Jorn Lotsch

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. ncbi Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 144:119-24. 2009
  2. ncbi Pharmacokinetics of non-intravenous formulations of fentanyl
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, J W Goethe University Hospital, Theodor Stern Kai 7, 60590, Frankfurt, Germany
    Clin Pharmacokinet 52:23-36. 2013
  3. ncbi The human operculo-insular cortex is pain-preferentially but not pain-exclusively activated by trigeminal and olfactory stimuli
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    PLoS ONE 7:e34798. 2012
  4. ncbi Self-ratings of higher olfactory acuity contrast with reduced olfactory test results of fibromyalgia patients
    Jorn Lotsch
    Institute of Clinical Pharmacology, Goethe University, D 60590 Frankfurt am Main, Germany Electronic address
    Int J Psychophysiol 86:182-6. 2012
  5. ncbi Extended cortical activations during evaluating successive pain stimuli
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Soc Cogn Affect Neurosci 7:698-707. 2012
  6. ncbi Sniffing out pharmacology: interactions of drugs with human olfaction
    Jorn Lotsch
    pharmazentrum frankfurt and Center for Drug Research, Development and Safety ZAFES, Institute of Clinical Pharmacology, Goethe University Hospital, D 60590 Frankfurt am Main, Germany
    Trends Pharmacol Sci 33:193-9. 2012
  7. ncbi Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Clin Pharmacokinet 43:983-1013. 2004
  8. ncbi A critical appraisal of human genotyping for pain therapy
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Trends Pharmacol Sci 31:312-7. 2010
  9. ncbi Are mu-opioid receptor polymorphisms important for clinical opioid therapy?
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Trends Mol Med 11:82-9. 2005
  10. ncbi [Are polymorphisms in the mu-opioid receptor important for opioid therapy?]
    J Lotsch
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Schmerz 19:378-82, 384-5. 2005

Collaborators

Detail Information

Publications95

  1. ncbi Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 144:119-24. 2009
    ..However, to make codeine therapy safe, extremely high morphine formation has to be predicted as well, which has to be obtained at the effort of combining genotyping with phenotyping...
  2. ncbi Pharmacokinetics of non-intravenous formulations of fentanyl
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, J W Goethe University Hospital, Theodor Stern Kai 7, 60590, Frankfurt, Germany
    Clin Pharmacokinet 52:23-36. 2013
    ....
  3. ncbi The human operculo-insular cortex is pain-preferentially but not pain-exclusively activated by trigeminal and olfactory stimuli
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    PLoS ONE 7:e34798. 2012
    ....
  4. ncbi Self-ratings of higher olfactory acuity contrast with reduced olfactory test results of fibromyalgia patients
    Jorn Lotsch
    Institute of Clinical Pharmacology, Goethe University, D 60590 Frankfurt am Main, Germany Electronic address
    Int J Psychophysiol 86:182-6. 2012
    ..However, as reduced activations in some brain areas also seem to accompany FM, a multisensory hypersensitivity is not a necessary consequence...
  5. ncbi Extended cortical activations during evaluating successive pain stimuli
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Soc Cogn Affect Neurosci 7:698-707. 2012
    ....
  6. ncbi Sniffing out pharmacology: interactions of drugs with human olfaction
    Jorn Lotsch
    pharmazentrum frankfurt and Center for Drug Research, Development and Safety ZAFES, Institute of Clinical Pharmacology, Goethe University Hospital, D 60590 Frankfurt am Main, Germany
    Trends Pharmacol Sci 33:193-9. 2012
    ..With an established molecular basis and using available tools, the assessment of olfaction in drug development and approval is advised...
  7. ncbi Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Clin Pharmacokinet 43:983-1013. 2004
    ..Nonetheless, at a limited level, pharmacogenetics can be expected to facilitate individualised opioid therapy...
  8. ncbi A critical appraisal of human genotyping for pain therapy
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Trends Pharmacol Sci 31:312-7. 2010
    ..After more than a decade of identifying genetic associations, the current challenge is to intensify compilation of this information for precisely defined clinical settings for which improved pain treatment is possible...
  9. ncbi Are mu-opioid receptor polymorphisms important for clinical opioid therapy?
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Trends Mol Med 11:82-9. 2005
    ..The accumulated evidence provides a solid basis for continuing research that should address the underlying molecular mechanisms and the role and benefits of OPRM1 genotyping for clinical pain therapy...
  10. ncbi [Are polymorphisms in the mu-opioid receptor important for opioid therapy?]
    J Lotsch
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Johann Wolfgang Goethe Universitat, Frankfurt am Main
    Schmerz 19:378-82, 384-5. 2005
    ....
  11. ncbi A GTP cyclohydrolase 1 genetic variant delays cancer pain
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 148:103-6. 2010
    ..This suggests the future possibility of using partial GCH1 blockade or BH4 inhibition as a prophylactic to prevent or delay the development of cancer pain...
  12. ncbi Programming of a flexible computer simulation to visualize pharmacokinetic-pharmacodynamic models
    J Lotsch
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Int J Clin Pharmacol Ther 42:15-22. 2004
    ....
  13. ncbi Relevance of frequent mu-opioid receptor polymorphisms for opioid activity in healthy volunteers
    J Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Pharmacogenomics J 6:200-10. 2006
    ..This applies to opioid potency in the context of opioid therapy but not to pain processing or substance addiction, in which opioid receptors are involved but other or additional OPRM1 mutations may be important...
  14. ncbi Current evidence for a genetic modulation of the response to analgesics
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Pain 121:1-5. 2006
  15. ncbi Current evidence for a modulation of nociception by human genetic polymorphisms
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 132:18-22. 2007
  16. ncbi Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 51:3264-72. 2007
    ..It may be contemplated in cases with constitutional side effects or low CD4 counts with weak immune responses...
  17. ncbi [Who likes placebo?]
    J Lotsch
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Johann Wolfgang Goethe Universitat, Theodor Stern Kai 7, 60590, Frankfurt am Main
    Anaesthesist 57:445-6. 2008
  18. ncbi Cross-sectional analysis of the influence of currently known pharmacogenetic modulators on opioid therapy in outpatient pain centers
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Pharmacogenet Genomics 19:429-36. 2009
    ..We analyzed the imprint of these variants in opioid therapy in a highly variable cohort of pain patients treated in outpatient units to test whether genotyping may play a role in this clinical setting...
  19. ncbi Fatal respiratory depression after multiple intravenous morphine injections
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Maine, Germany
    Clin Pharmacokinet 45:1051-60. 2006
    ....
  20. ncbi Genetic modulation of the pharmacological treatment of pain
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pharmacol Ther 124:168-84. 2009
    ....
  21. ncbi The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain
    J Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University Frankfurt am Main, Frankfurt, Germany
    Clin Pharmacol Ther 85:25-30. 2009
    ....
  22. ncbi Bedside-to-bench pharmacology: a complementary concept to translational pharmacology
    J Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 87:647-9. 2010
    ..Both directions of reasoning may lead to independent yet comparable or even identical successes, and it is only by using both together that one gains the full benefit of human intellectual resources...
  23. ncbi Higher pain scores, similar opioid doses and side effects associated with antipyretic analgesics in specialised tertiary pain care
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    Inflamm Res 59:989-95. 2010
    ..To evaluate whether non-opioid antipyretic analgesics are associated with lower pain scores, opioid doses and side effects in pain patients in tertiary care...
  24. ncbi Simultaneous screening for three mutations in the ABCB1 gene
    Jorn Lotsch
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Genomics 82:503-10. 2003
    ..e., C/T1236, G/T2677, C/T3435. The next most frequent genotypes were a homozygous nonmutated genotype, with 20%, and a homozygous mutated genotype, with 13%...
  25. ncbi Genetic variability of pain perception and treatment--clinical pharmacological implications
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Eur J Clin Pharmacol 67:541-51. 2011
    ..These developments show that genotyping information obtained from studies on pain patients plays a role in the clinical pharmacology of pain...
  26. ncbi Verapamil decreases glucuronidase activity in the gut
    Jorn Lotsch
    Pharmazentrum Frankfurt, Department of Clinical Pharmacology, Johann Wolfgang Goethe University Hospital, Theodor Stern Kai, D 60590 Frankfurt, Germany
    Biochem Pharmacol 63:1575-8. 2002
    ..This indicates that verapamil is not suited as P-gp inhibitor in experiments involving glucuronides. An increase in the intestinal absorption of M6G due to P-gp-inhibition was not observed at the verapamil dose studied...
  27. ncbi Drug interactions with patient-controlled analgesia
    Jorn Lotsch
    Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt, Germany
    Clin Pharmacokinet 41:31-57. 2002
    ....
  28. ncbi The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine
    Jorn Lotsch
    Pharmazentrum Frankfurt, Johann Wolfgang Goethe University, Frankfurt, Germany
    Pharmacogenetics 12:3-9. 2002
    ..In contrast, the concentration-response relationship of morphine was not affected by this specific SNP. The A118G SNP in the mu-receptor gene significantly reduces the potency of M6G in humans...
  29. ncbi The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers
    J Lotsch
    Department of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Anesthesiology 95:1329-38. 2001
    ..This study was aimed at the quantification of the transfer half-life (t(1/2,ke0)) of this delay...
  30. ncbi Population pharmacokinetics of fast release oral diclofenac in healthy volunteers: relation to pharmacodynamics in an experimental pain model
    J Lotsch
    Stanford University School of Medicine, Department of Anesthesia, California 94305 5640, USA
    Pharm Res 17:77-84. 2000
    ..Population pharmacokinetics of a fast release diclofenac were assessed with special focus on pharmacodynamic implications...
  31. ncbi Effects of the opioid remifentanil on olfactory function in healthy volunteers
    J Lotsch
    pharmazentrumfrankfurt, Department of Clinical Pharmacology, Johann Wolfgang Goethe University, Germany
    Life Sci 69:2279-85. 2001
    ..We conclude that opioid administration leads to impaired olfactory function expressed in raised olfactory thresholds. This is compatible with previously reported opioidergic effects at the level of the olfactory bulb...
  32. ncbi Morphine-6-glucuronide: an analgesic of the future?
    J Lotsch
    Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Clin Pharmacokinet 40:485-99. 2001
    ....
  33. ncbi The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats
    Jorn Lotsch
    Pharmazentrum Frankfurt, Department of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Neurosci Lett 329:145-8. 2002
    ....
  34. ncbi Pharmacogenetics of new analgesics
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    Br J Pharmacol 163:447-60. 2011
    ..The increased number of candidate pharmacogenetic modulators of analgesic actions may open opportunities for the broader clinical implementation of genotyping information...
  35. ncbi A KCNJ6 (Kir3.2, GIRK2) gene polymorphism modulates opioid effects on analgesia and addiction but not on pupil size
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, Frankfurt am Main, Germany
    Pharmacogenet Genomics 20:291-7. 2010
    ..2, GIRK2) is important for opioid receptor transmission. The KCNJ6 rs2070995 AA genotype has been associated with increased opioid analgesic requirements in Japanese. We analyzed its consequences for other opioid effects...
  36. ncbi Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University Hospital, Theodor Stern Kai 7, D 60590 Franfurt am Main, Germany
    Pharmacogenomics 12:1729-40. 2011
    ....
  37. ncbi Low-dose drug combinations along molecular pathways could maximize therapeutic effectiveness while minimizing collateral adverse effects
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    Drug Discov Today 16:1001-6. 2011
    ..Intentionally using intelligent low-dose drug combinations might provide an innovative therapeutic concept that directs combined small-drug effects towards a large, selective clinical effect with minor collateral damage...
  38. ncbi Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 79:72-89. 2006
    ....
  39. ncbi Cross-sectional assessment of the consequences of a GTP cyclohydrolase 1 haplotype for specialized tertiary outpatient pain care
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin J Pain 25:781-5. 2009
    ..We addressed the question whether this genetic association plays a role in outpatient pain therapy...
  40. ncbi Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers
    Carsten Skarke
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Germany
    Clin Pharmacol Ther 73:107-21. 2003
    ..Our objective was to quantify the extent and time course of the effects of morphine-6-glucuronide and morphine on pain threshold, pain tolerance, pupil diameter, and side effects...
  41. ncbi Screening for IL28B gene variants identifies predictors of hepatitis C therapy success
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt, Germany
    Antivir Ther 15:1099-106. 2010
    ..Because HCV affects 170 million people worldwide and is a leading cause of cirrhosis and hepatocellular carcinoma, screening for prognostic factors in routine clinical practice requires rapid and reliable assays...
  42. ncbi Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir
    Wolf Peter Hofmann
    Department of Internal Medicine I, Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 16:695-704. 2011
    ..Ribavirin increases early and sustained virological response rates in patients chronically infected with HCV who receive pegylated interferon-α and novel HCV protease inhibitors...
  43. ncbi Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University Hospital, Frankfurt am Main, Germany
    Pharmacogenet Genomics 21:289-96. 2011
    ....
  44. ncbi Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype
    Irmgard Tegeder
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Eur J Pain 12:1069-77. 2008
    ..The present study aimed at (i) testing this hypothesis and (ii) independently reproducing the pain-decreasing effects of a particular GCH1 haplotype having been previously associated with pain protection...
  45. ncbi Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers
    Carsten Skarke
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Pharmacogenetics 13:651-60. 2003
    ..Mutations in the ABCB1 gene have been associated with decreased expression and net function of P-glycoprotein (P-gp). We investigated the modulation of the central nervous effects of loperamide resulting from ABCB1 genetic variants...
  46. ncbi Analgesic efficacy of tramadol, pregabalin and ibuprofen in menthol-evoked cold hyperalgesia
    Kosta Altis
    Pharmazentrum frankfurt ZAFES, Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main, Frankfurt am Main, Germany
    Pain 147:116-21. 2009
    ....
  47. ncbi Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?
    Jorn Lotsch
    Pharmazentrum Frankfurt, Department of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Anesthesiology 97:814-9. 2002
    ....
  48. ncbi Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Pharmacol Ther 79:35-48. 2006
    ..Our objective was to investigate whether codeine or one of its metabolites contributes substantially to central nervous effects independent from the cytochrome P450 (CYP) 2D6-mediated O-demethylation to morphine...
  49. ncbi Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients
    Christoph Sarrazin
    Medizinische Klinik 1, J W Goethe University Hospital, Frankfurt am Main, Germany
    J Hepatol 54:415-21. 2011
    ..The importance of three IL28B single nucleotide polymorphisms (rs8099917, rs12980275 and rs12979860) for HCV genotype 2/3-infected patients is unknown...
  50. ncbi Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers
    Jorn Lotsch
    Department of Clinical Pharmacology, Pharmazentrum Frankfurt, Johann Wolfgang Goethe University, Theodor Stern Kai 7, Frankfurt, Germany D 60590
    Clin Pharmacol Ther 72:151-62. 2002
    ..This investigation focused on the development of a predictive model of morphine, including morphine-6-glucuronide (M6G) for healthy young volunteers after morphine administration...
  51. ncbi Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein
    Jorn Lotsch
    Pharmazentrum Frankfurt, Department of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    J Neurochem 83:241-8. 2002
    ..Antinociceptive effects of M6G were significantly enhanced by inhibition of P-gp. Inhibition of P-gp alters the transport of M6G across the blood-brain barrier, resulting in enhanced spinal cord uptake and enhanced antinociception...
  52. ncbi Inhibition of GTP cyclohydrolase reduces cancer pain in mice and enhances analgesic effects of morphine
    Geethanjali Pickert
    Pharmazentrum Frankfurt, ZAFES, Institut fur Klinische Pharmakologie, Klinikum der Goethe Universität Frankfurt, Theodor Stern Kai 7, Hs 74, 60590 Frankfurt, Germany
    J Mol Med (Berl) 90:1473-86. 2012
    ....
  53. ncbi A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers
    Johannes Vermehren
    Pharmazentrum frankfurt ZAFES, Institut fur Klinische Pharmakologie, Klinikum der J W Goethe Universitat, Frankfurt am Main, Germany
    PLoS ONE 7:e32605. 2012
    ..Most significant associations were observed for the A alleles of HLA-DPA1 rs3077 and HLA-DPB1 rs9277535, which conferred a decreased risk for HBV infection. We assessed the implications of these variants for HBV infection in Caucasians...
  54. ncbi Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Chem 53:1010-5. 2007
    ..A haplotype in the GTP cyclohydrolase 1 (dopa-responsive dystonia) gene (GCH1) is associated with decreased persistent pain. The aim of the present study was to develop a screening method for the pain-protective haplotype...
  55. ncbi Rapid screening for potentially relevant polymorphisms in the human fatty acid amide hydrolase gene using Pyrosequencing
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Prostaglandins Other Lipid Mediat 84:128-37. 2007
    ..We therefore developed reliable high-throughput screening assays for FAAH polymorphisms to facilitate research of their clinical role...
  56. ncbi The mu-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans
    Jorn Lotsch
    Department of Clinical Pharmacology, Pharmazentrum Frankfurt, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Pain 102:151-61. 2003
    ..Absence of brush-evoked and electrical hyperalgesia is compatible with the view that mechanical hyperalgesia to blunt and punctuated stimulation of the freeze lesion is predominantly caused by a peripheral mechanism...
  57. ncbi Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients
    Nils von Hentig
    Pharmazentrum Frankfurt, Department of Virology, JohannWolfgang Goethe University Hospital, Frankfurt, Germany
    Antivir Ther 12:1237-46. 2007
    ..To evaluate predictive factors for therapy outcome of a boosted double-protease inhibitor (PI) regimen in 58 extensively pre-treated patients with HIV...
  58. ncbi Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Frankfurt am Main, Germany
    Pharmacogenet Genomics 19:407-14. 2009
    ....
  59. ncbi Peripheral opioid analgesia in experimental human pain models
    Irmgard Tegeder
    Pharmazentrum Frankfurt, Institut fur Klinische Pharmakologie, Klinikum der Johann Wolfgang Goethe Universitat, Frankfurt am Main, Germany
    Brain 126:1092-102. 2003
    ..Since this occurs at concentrations that do not cause central opioid effects, M6G might be useful as a peripheral opioid analgesic...
  60. ncbi The human mu-opioid receptor gene polymorphism 118A > G decreases cortical activation in response to specific nociceptive stimulation
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Behav Neurosci 120:1218-24. 2006
    ..6% of the cases as carriers or noncarriers of the allele. The OPRM1 118A > G polymorphism specifically modulates nociceptive but not nonnociceptive cortical activation...
  61. ncbi The clinical significance of electrophysiological measures of olfactory function
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Behav Brain Res 170:78-83. 2006
    ..To establish the detectability of olfactory event-related potentials (OERP) in relation to the results from psychophysical tests of olfactory function...
  62. ncbi A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain
    Bruno Georg Oertel
    Institute of Clinical Pharmacology, Pharmazentrum frankfurt ZAFES, Goethe University, Frankfurt am Main, Germany
    J Biol Chem 284:6530-5. 2009
    ..001). The thalamus was unaffected by the OPRM1 118A>G SNP. In conclusion, we provide a molecular basis for the reduced clinical effects of opioid analgesics in carriers of mu-opioid receptor variant N40D...
  63. ncbi The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 78:278-87. 2005
    ..The effects in rats have been seen with the 5-hydroxytryptamine 4a (5-HT4a) agonist BIMU8, which is currently not available for use in humans...
  64. ncbi Principle components analysis of pain thresholds to thermal, electrical, and mechanical stimuli suggests a predominant common source of variance
    Till J Neddermeyer
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 138:286-91. 2008
    ..We conclude that characterizing a person as being generally stoical or complaining to any painful stimulus appears to be justified at least at pain threshold level...
  65. ncbi Pyrosequencing of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance
    Carsten Skarke
    Johann Wolfgang Goethe University, Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Pharmacogenomics 8:1643-60. 2007
    ..The aim of this study was to develop rapid and reliable screening assays for PTGS2 mutations with reported clinical consequences...
  66. ncbi Pyrosequencing-based screening for genetic polymorphisms in cytochrome P450 2B6 of potential clinical relevance
    Maren Rohrbacher
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Pharmacogenomics 7:995-1002. 2006
    ..Therefore, we aimed at providing genetic screening assays for these three SNPs...
  67. ncbi Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine
    Carsten Skarke
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 74:303-11. 2003
    ..Our objective was to evaluate whether P-glycoprotein inhibition after quinidine pretreatment results in modified central nervous effects of morphine...
  68. ncbi Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 52:2273-5. 2008
    ..Therefore, patients should be selected carefully for this regimen and frequent clinical and therapeutic drug monitoring is strongly advised...
  69. ncbi Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection
    Christian M Lange
    Medizinische Klinik 1, Klinikum der J W Goethe Universität Frankfurt am Main, D 60590 Frankfurt am Main, Germany
    J Hepatol 55:322-7. 2011
    ..We therefore, aimed to explore the impact of donor and recipient genotypes of these polymorphisms on hepatitis C virus (HCV) liver graft reinfection...
  70. ncbi Pharmacokinetic-pharmacodynamic modeling of the miotic effects of dihydrocodeine in humans
    Helmut Schmidt
    Pharmazentrum frankfurt ZAFES, Institute for Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 63:1045-54. 2007
    ..The purpose of this study was to evaluate the pharmacokinetic-pharmacodynamic interrelations of pupillary effects of dihydrocodeine by two different analytic approaches...
  71. ncbi Pharmacokinetics of morphine are not altered in subjects with Gilbert's syndrome
    Carsten Skarke
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Br J Clin Pharmacol 56:228-31. 2003
    ..To verify that Gilbert's syndrome, which is caused by decreased glucuronidation capacity of the UDP-glucuronosyl transferase (UGT)1A1, does not account for impaired morphine clearance...
  72. ncbi Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults
    Nils von Hentig
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Antimicrob Agents Chemother 53:3524-7. 2009
    ..In contrast, age, sex, weight, pregnancy, and the pharmaceutical formulation exerted only minor, nonsignificant effects...
  73. ncbi Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing
    Maren Rohrbacher
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Pharmacogenomics 7:167-76. 2006
    ....
  74. ncbi Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing
    Carsten Skarke
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    Eur J Clin Pharmacol 61:887-92. 2005
    ....
  75. ncbi Clinical genetics of functionally mild non-coding GTP cyclohydrolase 1 (GCH1) polymorphisms modulating pain and cardiovascular risk
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Mutat Res 659:195-201. 2008
    ....
  76. ncbi Genetic diagnostics of functional variants of the human dopamine D2 receptor gene
    Alexandra Doehring
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Psychiatr Genet 19:259-68. 2009
    ....
  77. ncbi The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production
    Carsten Skarke
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Clin Pharmacol Ther 80:621-32. 2006
    ..Our objective was to assess the role of the reportedly functional PTGS2 (prostaglandin-endoperoxide synthase 2/cyclooxygenase [COX] 2) promoter mutation -765G>C for the COX-2-inhibiting effects of celecoxib...
  78. ncbi Meta-analysis of the relevance of the OPRM1 118A>G genetic variant for pain treatment
    Carmen Walter
    Pharmazentrum frankfurt ZAFES, Institute for Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Pain 146:270-5. 2009
    ..This discourages basing personalized therapeutic concepts of pain therapy on OPRM1 118A>G genotyping at the present state of evidence...
  79. ncbi The partial 5-hydroxytryptamine1A receptor agonist buspirone does not antagonize morphine-induced respiratory depression in humans
    B G Oertel
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 81:59-68. 2007
    ..This is indicated by its lack of anti-respiratory depressive effects and by the buspirone-associated increase of morphine-induced nausea...
  80. ncbi Current evidence for a modulation of low back pain by human genetic variants
    Irmgard Tegeder
    Pharmazentrum frankfurt ZAFES, Klinikum der Johann Wolfgang Goethe Universität Frankfurt am Main, Frankfurt am Main, Germany
    J Cell Mol Med 13:1605-19. 2009
    ....
  81. ncbi Ceramide synthases and ceramide levels are increased in breast cancer tissue
    Susanne Schiffmann
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, 60590 Frankfurt am Main, Germany
    Carcinogenesis 30:745-52. 2009
    ..In conclusion, progression in breast cancer is associated with increased ceramide levels due to an upregulation of specific LASS genes...
  82. ncbi Tissue distribution of imipenem in critically ill patients
    Irmgard Tegeder
    Frankfurt Pharmacy Center, Johann Wolfgang Goethe University Clinic, Krankenhaus Nordwest, Theodor Stern Kai 7, 605290 Frankfurt am Main, Germany
    Clin Pharmacol Ther 71:325-33. 2002
    ..Most patients were >60 years old and had renal failure; most patients also had impaired liver, heart, or lung function...
  83. ncbi Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques
    Jürgen M Peters
    Department of Psychiatry and Psychotherapy I, University Hospital, Johann Wolfgang Goethe University of Frankfurt am Main, Heinrich Hoffmann Strasse 10, 60528 Frankfurt am Main, Germany
    Am J Psychiatry 160:1995-2002. 2003
    ..To clarify the olfactory deficit hypothesis regarding Alzheimer's disease, the authors compared olfactory function in patients with Alzheimer's disease, subjects with mild cognitive impairment, and healthy comparison subjects...
  84. ncbi Pharmacodynamics of orally administered sustained- release hydromorphone in humans
    M S Angst
    Department of Anesthesia, Stanford University School of Medicine, California 94305 5117, USA
    Anesthesiology 94:63-73. 2001
    ..This trial examined time course and magnitude of analgesia to experimental pain after administration of sustained-release hydromorphone as compared with that after immediate-release hydromorphone or placebo...
  85. ncbi Simultaneous fitting of R- and S-ibuprofen plasma concentrations after oral administration of the racemate
    J Lotsch
    Center of Pharmacology, Department of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt, Germany
    Br J Clin Pharmacol 52:387-98. 2001
    ..To assess the pharmacokinetic equivalence of two different formulations of ibuprofen lysinate with special focus on the expected effects...
  86. ncbi Selective antagonism of opioid-induced ventilatory depression by an ampakine molecule in humans without loss of opioid analgesia
    B G Oertel
    Pharmazentrum frankfurt ZAFES, Institute for Clinical Pharmacology, Goethe University Frankfurt am Main, Frankfurt am Main, Germany
    Clin Pharmacol Ther 87:204-11. 2010
    ..6 mg of naloxone. These results support the use of ampakines as selective antidotes in humans to counter opioid-induced ventilatory depression without affecting opioid-mediated analgesia...
  87. ncbi Single-step identification of all length polymorphisms in the UGT1A1 gene promoter
    C Skarke
    Pharmazentrum Frankfurt, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt, Germany
    Int J Clin Pharmacol Ther 42:133-8. 2004
    ....
  88. ncbi Comparison of two screening methods for in-house genotyping in clinical pharmacology units
    J Darimont
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt Main, Germany
    Int J Clin Pharmacol Ther 43:17-22. 2005
    ..8%. Although both methods were found suitable for rapid SNP detection, Pyrosequencing was the preferred method since it provides the nucleotide sequence directly thus facilitating interpretation...
  89. ncbi Different odor tests contribute differently to the evaluation of olfactory loss
    Jorn Lotsch
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, Frankfurt am Main, Germany
    Chem Senses 33:17-21. 2008
    ..In conclusion, combined testing of several components of olfaction, especially including assessment of thresholds, provides the most significant approach to the diagnosis of smell loss...
  90. ncbi Capsaicin or menthol sensitization induces quantitative but no qualitative changes to thermal and mechanical pain thresholds
    Karin Flühr
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin J Pain 25:128-31. 2009
    ....
  91. ncbi A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene
    S Grosch
    Pharmazentrum Frankfurt, Klinikum der Johann Wolfgang Goethe Universitat Frankfurt, Theodor Stern Kai7, 60590 Frankfurt Main, Germany
    Br J Clin Pharmacol 52:711-4. 2001
    ..Therefore, we wanted to develop a fast and reliable detection method for this SNP which is applicable in a clinical setting...
  92. ncbi Differential opioid action on sensory and affective cerebral pain processing
    B G Oertel
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Frankfurt am Main, Germany
    Clin Pharmacol Ther 83:577-88. 2008
    ..In contrast, in brain regions known to process the affective dimension of pain (parahippocampal gyrus, amygdala, anterior insula), pain-related activation disappeared at the lowest alfentanil dose, without genotype differences...
  93. ncbi Comparison of tissue concentrations after intramuscular and topical administration of ketoprofen
    I Tegeder
    Zentrum der Pharmakologie, , Frankfurt am Main, Germany
    Pharm Res 18:980-6. 2001
    ..Thus, the tissue concentrations of ketoprofen after topical administration can hardly explain the reported clinical efficacy of topical ketoprofen...
  94. ncbi Genetic mutations that prevent pain: implications for future pain medication
    Bruno Oertel
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Johann Wolfgang Goethe University, Theodor Stern Kai 7, 60590 Frankfurt am Main, Germany
    Pharmacogenomics 9:179-94. 2008
    ....
  95. ncbi Functional variants of the human 5-lipoxygenase gene and their genetic diagnosis
    Emanuel V Geiger
    Pharmazentrum frankfurt ZAFES, Institute of Clinical Pharmacology, Goethe University, Theodor Stern Kai 7, D 60590 Frankfurt am Main, Germany
    Prostaglandins Leukot Essent Fatty Acids 80:255-62. 2009
    ..The five-repeat genotype was the most frequent Sp1/Egr1 promoter tandem repeat variant (allelic frequency 84%). These assays and analyses provide a solid basis for future assessments of the genetic modulation of leukotriene production...